Impact Announced First-Patient-In of its PARP inhibitor IMP4297 in Phase 3 Study
Impact Therapeutics announced the phase 3 study of its PARP inhibitor IMP4297 had the first patient dosed recently. This study is a randomized, placebo-controlled, double-blinded, multi-center, phase 3 clinical study in China to evaluate the efficacy and safety of IMP4297 as the maintenance treatment in advanced ovarian cancer patients after first-line platinum-containing chemotherapy.
IMP4297 is a novel agent targeting PARP developed by Impact, with 2 phase 1 studies in China and Australia respectively. The phase 1 data readout was published in ASCO 2019, showing that IMP4297 has the potential to be the best PARP inhibitor with better safety profile and wider therapeutic window. Impact have also started a phase 2 pivotal study of IMP4297 single agent in treating advanced ovarian cancer patients with BRCA mutation who have received at least 2 prior lines of standard treatment.
Dr. Chih-Yi Hsieh, Senior Vice President and Chief Medical Officer, said, “It’s exciting that we started the Phase 3 trial for IMP4297. It is the first phase 3 trial of domestically developed PARP inhibitor as the maintenance treatment in first-line platinum-sensitive ovarian cancer patients. It’s also a great opportunity to bring the benefit of PARP inhibitor to more patients regardless of BRCA mutation status. We want to thank all the efforts and supports from investigators, clinical sites, CRO partners and team members. We will endeavor to advance the clinical development of IMP4297, maximize the advantage of IMP4297 and broaden the patients population who could benefit from this novel drug.
Impact Therapeutics is a privately held clinical-stage biopharmaceutical company incorporated in Nanjing, China, dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. Impact has assembled most comprehensive global DNA damage response (DDR) pipeline of novel drug candidates generated by in-house discovery platform, and now is expanding to other novel synthetic lethality targets to broaden pipeline coverage. Impact has raised $46 million USD up to date invested by recognized venture capital firms including Lilly Asia Ventures. Currently series D fundraising is ongoing.